AN2 Therapeutics Inc.
(ANTX)
undefined
undefined%
At close: undefined
1.40
-1.73%
After-hours Jan 03, 2025, 04:14 PM EST
Company Description
AN2 Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing treatments for rare, chronic, and serious infectious diseases.
It is developing epetraborole, a once-daily oral treatment for patients with chronic non-tuberculous mycobacterial lung disease.
The company was incorporated in 2017 and is headquartered in Menlo Park, California.
AN2 Therapeutics Inc.
| Country | United States |
| IPO Date | Mar 25, 2022 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 41 |
| CEO | Eric E. Easom |
Contact Details
Address: 1800 El Camino Real Menlo Park, California United States | |
| Website | https://www.an2therapeutics.com |
Stock Details
| Ticker Symbol | ANTX |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001880438 |
| CUSIP Number | 037326105 |
| ISIN Number | US0373261058 |
| Employer ID | 82-0606654 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Eric E. Easom | Co-Founder, Chief Executive Officer, President & Chairman of the Board |
| Lucy O. Day CPA | Chief Financial Officer, Principal Financial Officer & Principal Accounting Officer |
| Dr. George Harrison Talbot FACP, M.D. | Co-Founder & Senior Clinical Advisor |
| Dr. Michael R. K. Alley Ph.D. | Co-Founder & Head of Biology |
| Dr. Sanjay Chanda Ph.D. | Chief Development Officer |
| Joseph S. Zakrzewski | Co-Founder & Chairman of the Board |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Dec 23, 2024 | 4 | Filing |
| Dec 23, 2024 | 4 | Filing |
| Dec 23, 2024 | 4 | Filing |
| Dec 23, 2024 | 4 | Filing |
| Dec 23, 2024 | 4 | Filing |
| Dec 10, 2024 | 4 | Filing |
| Nov 27, 2024 | 4 | Filing |
| Nov 27, 2024 | 4 | Filing |
| Nov 21, 2024 | 4 | Filing |
| Nov 20, 2024 | 4 | Filing |